viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals gets a speeding ticket for 18% price increase

Over the past year, shares have come from 29 cents to be trading at around $1.90.

asx electronic board
Earlier this month, director Christopher Fullerton purchased 100,000 shares

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has responded to a Price Query from the ASX regarding its run from its $1.605 close Tuesday to $1.90 yesterday, a gain of 18.3%.

The company responded to the ASX saying it was not aware of any relevant information not released to the market.

Paradigm went on to say that it believes a number of factors provide a possible explanation for the recent trading.

READ: Paradigm Biopharmaceuticals director shows confidence with on-market share purchase

Paradigm wrote: “As previously reported, Paradigm Biopharmaceuticals Ltd (ASX: PAR) intends to report on the secondary endpoints to its Phase 2b osteoarthritis randomised, double-blind,  placebo-controlled, multicentred clinical trial (the Phase 2b OA Clinical Trial) in Q1/Q2 CY2019.

“On the 18th and 20th December 2018, Paradigm reported the top-line results to the Phase 2b OA Clinical Trial. The top-line results were positive with the primary end-point being achieved.

READ: Paradigm Biopharmaceuticals moving towards phase 2/3 MPS clinical trial

“At the same time it was disclosed that Paradigm would report the outcome of the Phase 2b OA Clinical Trial secondary endpoints in Q1/Q2 CY2019. As disclosed in the clinical trial protocol, the secondary endpoints that will be reported are:

1. Mean change in KOOS pain score from baseline to day 165 – which measures durability of effect for the drug up to approximately 6 months;
2. Mean percentage change in KOOS Activity of Daily Living (ADL) from baseline to day 165 – which measures daily activities such as walking, going up and down stairs etc;
3. Proportion of subjects with >50% reduction in KOOS pain from baseline to day 165 – which indicates the proportion of subjects receiving a very strong (>50%) clinically meaningful benefit;
4. Change in bone marrow lesion (BML) volume between pre-treatment MRI and posttreatment MRI at day 53 – is an objective and indisputable measure and indicates if the drug is working to slow the progression of the disease. An increasing BML indicates progression (worsening) of the disease whilst a decreasing BML indicates regression (improvement) of the disease.

“The complete and final data set has not yet been received by the Company and there is nothing new to report. However, the Company will report on the Phase 2b secondary endpoints when the final data is ready for disclosure to the market.

READ: Paradigm Biopharmaceuticals to court partners and licensees for OA drug commercialisation

“Due to the comprehensive nature of this secondary endpoint data it is expected to be of significant interest to both the investment community and the pharmaceutical industry, hence the increasing attention the company is receiving in the lead up to the release of these results.

“In addition, we also note technical analysis supports strong positive trading momentum, potentially further adding to the current interest in the company.”

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 3.13 AUD

Market: ASX
Market Cap: $614.29 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...


3 min read